Immatics (NASDAQ:IMTX) Shares Up 5.3% on Insider Buying Activity
Market Beat·- Immatics N.V. shares rose 5.3% on Friday, reaching $9.86 following a significant insider purchase by Director Perceptive Advisors Llc. - The director purchased 863,060 shares at an average price of $8.69 per share, totaling approximately $7,500,000. - Analysts currently maintain a consensus Moderate Buy rating for the stock with a target price of $20.60.Immatics (NASDAQ:IMTX) Shares Down 8% - Should You Sell?
Market Beat·- Immatics N.V. (NASDAQ: IMTX) shares traded down 8% to $8.5090 amid lower trading volume, following recent quarterly earnings reporting EPS of -$0.53 and revenue of $10.44 million. - The company maintains a market capitalization of $1.16 billion and a consensus analyst rating of Moderate Buy with a target price of $20.80. - Institutional investors and hedge funds, including Bank of America Corp DE, hold 64.41% of the company's stock.Immatics (NASDAQ:IMTX) Issues Earnings Results
Market Beat·- Immatics reported a quarterly EPS of ($0.53), missing the consensus estimate of ($0.43). - The company's stock opened at $9.25 on Tuesday, with a market cap of $1.24 billion. - Several institutional investors and hedge funds recently adjusted their stakes in the biotechnology company.Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday
Market Beat·- Immatics is scheduled to release its Q2 2026 financial results on Wednesday, August 12th, with analysts anticipating earnings of ($0.43) per share and revenue of $11.9030 million. - The clinical-stage biotechnology company currently holds a market capitalization of $1.26 billion and a consensus analyst rating of Moderate Buy with a price target of $20.80. - Institutional investors and hedge funds own 64.41% of the company's stock, following recent adjustments to their respective stakes.